Achieving Glycemic Goals With Addition of Incretin-based Therapies to Insulin in Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Achieving Glycemic Goals With Addition of Incretin-based Therapies to Insulin in Patients With Type 2 Diabetes Mellitus

Published:2014-06 Issue:6 Volume:347 Page:491-501
ISSN:0002-9629
Container-title:The American Journal of the Medical Sciences
language:en
Short-container-title:The American Journal of the Medical Sciences

Author:

Tibaldi Joseph

Publisher

Elsevier BV

Subject

General Medicine

Reference45 articles.

1. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes;UK Prospective Diabetes Study (UKPDS) Group;Lancet,1998

2. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

3. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

4. Importance of controlling diabetes early—the concept of metabolic memory, legacy effect and the case for early insulinisation;Ranjit Unnikrishnan;J Assoc Physicians India,2011

5. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes;Johnston;Diabetes Care,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancement of oral bioavailability of insulin using a combination of surface-modified inclusion complex and SNEDDS;Journal of Molecular Liquids;2022-12

2. Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes;Journal of Diabetes;2016-09-22

3. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?;Diabetes & Metabolism;2015-12

4. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making;Therapeutic Advances in Endocrinology and Metabolism;2014-10